NCT01126749 · MORE INFO

Limitations, agreements, and source contact

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer · Source last updated 2022-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: Due to the lack of a clear definition for PFS censoring rules and deviation from the statistical analysis plan relating to interim analyses, the PFS analysis was deemed unreliable and therefore data was not collected and reported.

point Of Contact

email: esi_oncmedinfo@eisai.com
organization: Eisai Inc.
phone: +1-888-274-2378
title: Eisai Medical Information

Complete source fields

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: Due to the lack of a clear definition for PFS censoring rules and deviation from the statistical analysis plan relating to interim analyses, the PFS analysis was deemed unreliable and therefore data was not collected and reported.

point Of Contact

email: esi_oncmedinfo@eisai.com
organization: Eisai Inc.
phone: +1-888-274-2378
title: Eisai Medical Information

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice